Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation

Wing Mann Ho, Cesar Reis, Onat Akyol, Gokce Yilmaz Akyol, Richard Applegate, Gary Stier, Robert Martin, John H. Zhang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality. Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.

Original languageEnglish (US)
Pages (from-to)1441-1459
Number of pages19
JournalCurrent Drug Targets
Volume18
Issue number12
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Reperfusion
Brain
Cerebrovascular Circulation
Stroke
Pharmacology
Tissue Plasminogen Activator
Brain Injuries
Blood
Morbidity
Mortality
Therapeutics

Keywords

  • Cerebral ischemia
  • Conversion
  • Hemorrhagic transformation
  • Prevention
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation. / Ho, Wing Mann; Reis, Cesar; Akyol, Onat; Akyol, Gokce Yilmaz; Applegate, Richard; Stier, Gary; Martin, Robert; Zhang, John H.

In: Current Drug Targets, Vol. 18, No. 12, 01.09.2017, p. 1441-1459.

Research output: Contribution to journalReview article

Ho, Wing Mann ; Reis, Cesar ; Akyol, Onat ; Akyol, Gokce Yilmaz ; Applegate, Richard ; Stier, Gary ; Martin, Robert ; Zhang, John H. / Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation. In: Current Drug Targets. 2017 ; Vol. 18, No. 12. pp. 1441-1459.
@article{262a2eae7fa741809194cfe4ad700053,
title = "Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation",
abstract = "Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality. Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.",
keywords = "Cerebral ischemia, Conversion, Hemorrhagic transformation, Prevention, Stroke, Treatment",
author = "Ho, {Wing Mann} and Cesar Reis and Onat Akyol and Akyol, {Gokce Yilmaz} and Richard Applegate and Gary Stier and Robert Martin and Zhang, {John H.}",
year = "2017",
month = "9",
day = "1",
doi = "10.2174/1389450117666160818115850",
language = "English (US)",
volume = "18",
pages = "1441--1459",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Pharmacological management options to prevent and reduce ischemic hemorrhagic transformation

AU - Ho, Wing Mann

AU - Reis, Cesar

AU - Akyol, Onat

AU - Akyol, Gokce Yilmaz

AU - Applegate, Richard

AU - Stier, Gary

AU - Martin, Robert

AU - Zhang, John H.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality. Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.

AB - Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality. Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.

KW - Cerebral ischemia

KW - Conversion

KW - Hemorrhagic transformation

KW - Prevention

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85029679997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029679997&partnerID=8YFLogxK

U2 - 10.2174/1389450117666160818115850

DO - 10.2174/1389450117666160818115850

M3 - Review article

C2 - 27538508

VL - 18

SP - 1441

EP - 1459

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -